Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
MELBOURNE, Australia, Oct. 17, 2017 (GLOBE NEWSWIRE) -- Immuron Limited (ASX:IMC) (NASDAQ:IMRN), an Australian microbiome biopharmaceutical company focused on developing and commercializing oral...
-
Company’s lead drug candidate IMM-124E is well-positioned to pioneer successful treatment for NASH and NAFLD, diseases for which there is no proven effective treatment Company provides overview of...
-
MELBOURNE, Australia, Aug. 15, 2017 (GLOBE NEWSWIRE) -- Australian microbiome biopharmaceutical company Immuron Limited (ASX:IMC) (NASDAQ:IMRN) is pleased to release to shareholders and investors...
-
Key Highlights Final approval for key first in-human Clinical Study for CDI treatment, by Israeli Ministry of HealthAn estimated 28,000 patients die each year from CDI infections in the USA...
-
MELBOURNE, Australia, July 10, 2017 (GLOBE NEWSWIRE) -- Australian biopharmaceutical company, Immuron Limited (ASX:IMC) (NASDAQ:IMRN), is pleased to announce safety and efficacy results of the...
-
MELBOURNE, Australia, June 08, 2017 (GLOBE NEWSWIRE) -- Australian biopharmaceutical company Immuron Limited (ASX:IMC) (NASDAQ:IMRN), today announced the pricing of its initial public offering in...
-
Significant and clear beneficial biological effect of IMM-124E in the Acute Colitis modelResults add to the already existing body of evidence of IMM-124E’s strong anti-inflammatory properties ...
-
MELBOURNE, Australia, Feb. 20, 2017 (GLOBE NEWSWIRE) -- Immuron Limited (ASX:IMC), an Australian biopharmaceutical company focused on oral immunotherapy utilizing polyclonal antibody products to...
-
MELBOURNE, Australia, Jan. 19, 2017 (GLOBE NEWSWIRE) -- Australian biopharmaceutical Company Immuron Limited (ASX:IMC) is pleased to announce the initiation of several studies designed to add to the...
-
MELBOURNE, Australia, Jan. 18, 2017 (GLOBE NEWSWIRE) -- Immuron Limited (ASX:IMC) (the “Company”) wishes to advise investors that European and US-based Life Sciences Research and Analyst firm Van...